Fulton Breakefield Broenniman’s Novartis NVS Stock Holding History

Fulton Breakefield Broenniman’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-51,521	Closed	-$3.36M	–	113
2016 Q4	$3.36M	Sell	51,521 -1,714	-3%	-$111K	0.67%	58
2016 Q3	$3.77M	Buy	53,235 +387	+0.7%	+$28.2K	0.76%	56
2016 Q2	$3.91M	Buy	52,848 +1,342	+3%	+$92.7K	0.8%	55
2016 Q1	$3.34M	Buy	51,506 +3,422	+7%	+$233K	0.73%	55
2015 Q4	$3.71M	Buy	48,084 +1,350	+3%	+$107K	0.82%	52
2015 Q3	$3.85M	Sell	46,734 -1,279	-3%	-$114K	0.91%	51
2015 Q2	$4.23M	Buy	48,013 +1,668	+4%	+$153K	0.93%	50
2015 Q1	$4.09M	Buy	46,345 +1,551	+3%	+$138K	0.91%	47
2014 Q4	$3.72M	Buy	44,794 +859	+2%	+$71.2K	0.81%	51
2014 Q3	$3.71M	Buy	43,935 +1,126	+3%	+$91.1K	0.87%	50
2014 Q2	$3.47M	Sell	42,809 -1,087	-2%	-$85.5K	0.84%	49
2014 Q1	$3.34M	Buy	43,896 +1,376	+3%	+$100K	0.86%	48
2013 Q4	$3.06M	Buy	42,520 +1,431	+3%	+$99.5K	0.81%	48
2013 Q3	$2.82M	Buy	41,089 +1,602	+4%	+$106K	0.76%	48
2013 Q2	$2.5M	Buy	+39,487	New	+$2.57M	0.73%	52

Other funds holding NVS

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $22.8B AUM 25.09% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Fulton Breakefield Broenniman's NVS Position: Q1 2017 in Review

Fulton Breakefield Broenniman sold out of Novartis (NVS) in Q1 2017, closing a stake of 51,521 shares — an estimated $3.36M sold.

Fulton Breakefield Broenniman first reported a position in NVS in Q2 2013 and held it in 15 quarters. The position peaked at $4.23M in Q2 2015. 910 funds tracked by Wall St. Rank hold NVS as of Q1 2017.

Fulton Breakefield Broenniman reported no remaining Novartis position as of Q1 2017 after selling out during the quarter.
Fulton Breakefield Broenniman sold 51,521 Novartis shares in Q1 2017, an estimated $3.36M.
Fulton Breakefield Broenniman first reported a position in Novartis in Q2 2013 and held it in 15 quarters.
Fulton Breakefield Broenniman's Novartis position peaked at $4.23M in Q2 2015.
910 funds tracked by Wall St. Rank held Novartis as of Q1 2017.

Based on Fulton Breakefield Broenniman's 13F filing for Q1 2017, filed 27 Apr 2017.